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The effects of adjuvant therapies for sepsis on hepatic and renal
function: a retrospective analysis of 108 ICU patients
Berit Gökçe CEYLAN1, Lütfi YAVUZ1, Füsun EROĞLU1, Şenol GÜLMEN2, Ömer Rıdvan TARHAN3,
Adnan ALACA1

Aim: As liver and kidney failure have a direct effect on mortality, morbidity, and intensive care unit (ICU) length of stay
in sepsis patients, maintaining their functions or minimizing the degree of failure should be one of the most important
goals of therapy. In this retrospective study we investigated the effects of recently introduced adjuvant therapies on
hepatorenal functions in septic ICU patients.
Materials and methods: We conducted comparative and retrospective data analysis of 108 patients with sepsis that were
followed-up during a 2-year period in the ICU. We recorded AST, ALT, ALP, albumin, bilirubin, and INR in order to
evaluate variations in hepatic functions, and we recorded creatinine, BUN, and mean hourly urinary output in order to
evaluate variations in renal functions in patients that received standard antibiotherapy only (ST group), in those that
received polyvalent IgM-enriched immunoglobulin therapy added to standard antibiotherapy (IVIg group), and in those
that received recombinant human-activated protein C therapy added to standard antibiotherapy (APC group). Variables
at the beginning of the treatments and 96 h post-treatment were assessed.
Results: In total, 108 patients were analyzed (IVIg group: n = 20 in; APC: group n = 22; ST group: n = 66). The groups
were homogeneous in terms of initial hepatic and renal functions, according to AST, ALT, albumin, INR, bilirubin, BUN,
creatinine, and mean hourly urinary output. In the APC group the AST level at 96 h was significantly lower than that at
baseline (0 h), and in the ST group 96-h bilirubin was lower than that at baseline (0 h) (P = 0.035 and P = 0.015,
respectively).
Conclusion: We retrospectively observed that the adjuvant therapies did not improve hepatorenal functions in our ICU
septic patients.
Key words: Sepsis, hepatic functions, renal functions, activated protein C, intravenous immunoglobulin

Sepsiste uygulanan destek tedavilerin karaciğer ve böbrek fonksiyonlarına etkisinin
değerlendirilmesi: yoğun bakımda 108 hastanın retrospektif analizi
Amaç: Böbrek ve karaciğer yetmezliği sepsiste mortalite, morbidite ve yoğun bakım ünitesi (YBÜ) kalış süreleri üzerinde
direkt etkili olduğundan organ fonksiyonlarını korumak ya da yetmezliğin derecesini minimuma indirmek tedavinin en
önemli hedeflerinden biri olmalıdır. Bu retrospektif çalışmada yakın zamanda kullanıma giren adjuvan tedavilerin YBÜ
sepsis hastalarında karaciğer ve böbrek fonksiyonları üzerindeki etkilerini araştırdık.
Yöntem ve gereç: Bu çalışma YBÜ’ de 2 yıllık periyotta sepsis tanısı ile takip edilen 108 hastanın kayıtlarının
karşılaştırmalı ve retrospektif bir analizidir. Standart antibiyoterapi uygulanan (Grup ST) hastalarda, standart
antibiyoterapiye ek olarak Polivalan IgM ile zenginleştirilmiş immunoglobulin tedavisi uygulananlarda (Grup IVIG) ve
standart antibiyoterapiye ek olarak Rekombinant insane aktive protein C tedavisi uygulananlarda (Grup APC) karaciğer
fonksiyonlarındaki değişiklikleri değerlendirmek için AST, ALT, ALP, albümin, bilirübin ve INR değerlerini, böbrek
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fonksiyonlarını değerlendirmek için kreatinin, BUN ve saatlik ortalama idrar çıkışını kayıt ettik. Tedavilerin başlangıcında
ve tedavi başlangıcından 96 saat sonraki değişkenler değerlendirmeye alındı.
Bulgular: APACHE II skoru 25 ve üzerinde olan toplam 108 hasta (Grup IVIg n = 20, Grup APC n = 22 ve Grup ST n
= 66) analiz edildi. Gruplar AST, ALT, albümin, INR, bilirübin, BUN, kreatinin ve saatlik ortalama idrar çıkışı ile
değerlendirilen karaciğer ve böbrek fonksiyonlarının başlangıç değerleri açısından benzerdi. Grup APC de 96. saat AST
değeri bazal (sıfırıncı saat) değerlerine gore, Grup ST de ise 96. saat bilirübin değerleri bazal (sıfırıncı saat) değerlere
göre anlamlı düşük bulundu (sırasıyla P = 0,035 ve 0,015).
Sonuç: Adjuvan tedavilerin sepsis hastalarımızda karaciğer ve böbrek fonksiyonlarını iyileştirmediğini gözledik.
Anahtar sözcükler: Sepsis, karaciğer fonksiyonları, böbrek fonksiyonları, aktive protein C, intravenöz immunglobulin

Introduction
Sepsis is a clinical syndrome that complicates
severe infection, and is characterized by systemic
inflammation and widespread tissue injury (1). The
syndrome is a process rather than an event; there is a
spectrum of multiple organ dysfunction, with
incremental degrees of physiological derangement in
individual organs. Alteration in organ function can
vary widely, from a mild degree of organ dysfunction
to complete organ failure. Pulmonary failure, and liver
and kidney failure have a direct effect on mortality,
morbidity, and intensive care unit (ICU) length of stay
(2). Sepsis is the most common cause of the
progression of multiple organ dysfunction syndrome
(MODS), and the kidneys and liver are the most
important organs affected. Acute renal injury is a
frequent and serious complication of sepsis in ICU
patients, and is associated with a very high mortality
rate (3). Moreover, experimental studies have
indicated that hepatic oxidative and synthetic
metabolism may decrease, and that hepatocellular
dysfunction occurs soon after sepsis (4,5).
Therefore, preventing organ failure or minimizing
the degree of failure should be one of the most
important goals of any therapy for sepsis. Despite the
evolution of supportive therapy, and the use of new and
potent antibiotics, there has been little impact on
lowering the mortality rate due to sepsis. Consequently,
attempts have been made to lower the mortality rate
with new adjuvant therapies that have a modulating
role on the inflammatory response to sepsis. In this
regard, immunoglobulins were reported to be very
effective (6-9). Immunoglobulins, administered
intravenously (a novel therapeutic approach to
modulating immune response), have been shown to
exhibit anti-inflammatory properties in sepsis (10).
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Another adjuvant therapy, namely recombinant
human activated protein C (rhAPC), is currently the
only medicine for the treatment of severe sepsis
approved by the US Food and Drug Administration
(FDA), and only for high-risk patients (11). The
recently introduced drug remarkably improved the
outcome of septic patients (12). To the best of our
knowledge there have not been any retrospective or
prospective trials related to the specific role of this
agent on hepatic and renal dysfunction in septic
patients.
The aim of the present retrospective study was to
determine the effects of standard antibiotherapy alone
and with the addition of adjuvant therapies (IgMenriched immunoglobulin and rhAPC) on
hepatorenal functions in septic patients followed-up
in our ICU from January 2004 to January 2006.
Materials and methods
Study population and treatment regimens
This retrospective observational study was
conducted at Süleyman Demirel University Hospital,
Isparta, Turkey, which is a tertiary care facility with
19 ICU beds. Informed consent was waived and data
were obtained in an anonymous manner. Data
collected on all patients that were admitted to our
medical-surgical ICU between January 2004 and
January 2006 were reviewed to identify all patients
diagnosed with sepsis at any point during their ICU
stay. In all, 108 patients aged between 18 and 90 years
with severe sepsis were retrospectively identified.
Patient acuity was determined using the Acute
Physiology and Chronic Health Evaluation
(APACHE) II survival probability score. The inclusion
criteria were fulfilling the previously validated high-
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risk criterion of an APACHE II (13) score ≥25 and
severe sepsis (temperature >38 °C or <36 °C, heart
rate >90 beat/min, respiratory rate >20 breath/min or
PaCO2 <32 mmHg, white blood cell count
>12,000/mm3 or <4000/mm3, documented infection
and at least 1 positive blood culture following therapy
with at least 2 antibiotics in combination, and
dysfunction of an organ or hypotension). Data were
collected from the patients’ records.
The patients included in the study were
determined to have sepsis according to standard
definitions. Then the patients diagnosed with sepsis
were divided into 3 groups according to the therapy
they received beginning the day sepsis was diagnosed.
Patients treated with polyvalent IgM-enriched Ig
(pentaglobulin, Biotest AG, Dreieich, Germany) 5
mL/kg daily on 3 consecutive days constituted the
IVIg group. Patients treated with a 96-h course of
rhAPC (Xigris®, Eli Lilly and Co., Indianapolis, IN,
USA) 24 μg/kg/h beginning the day severe sepsis was
diagnosed constituted the APC group. Standard
antibiotherapy only (according to the hospital practice
guidelines) was administered to the ST group.
Supportive treatment consisted of fluid
resuscitation (fluids administered until central venous
pressure measurement reached 10-15 mmHg),
vasoactive drugs (when fluid administration failed to
restore an adequate arterial pressure: mean arterial
pressure above 60 mm Hg), and respiratory support
(protective mechanical ventilation in sepsis-related
patients in whom ALI/ARDS improved).
Measurements
Data for blood samples collected at 3 time intervals
were evaluated in all 3 study groups. Demographic
data included age, gender, total ICU length of stay, the
mortality rate in each group and the total mortality
rate, day of exitus, and admission category.
Additionally, data on the origin of each patient (from
where the patients were transported), prognostic
factors and comorbidity, APACHE II score at the time
therapy was initiated (APACHE II 0 h) and 96 h later
(APACHE II 96 h), bacterial gram species isolated (+/), CVP and MAP values at the beginning of therapy,
and 6 and 96 h later, volume of fluid infused daily,
serum glucose level, and diuretic and vasopressor
(VP) therapy were obtained from the patients’
records.

In order to assess renal and hepatic functions data
were recorded in all of the groups, as follows:
At the time a positive blood culture specimen was
obtained, which was when therapy began in each
patient.
96 h after a positive blood culture specimen was
obtained and therapy was initiated.
To evaluate hepatic functions in the septic patients
alanine transaminase (ALT), aspartate transaminase
(AST), alkaline phosphatase (ALP), albumin, INR,
and total bilirubin levels were recorded. For the
evaluation of renal functions in the septic patients
data for creatinine, blood urea nitrogen (BUN), and
mean hourly urinary output were recorded.
Statistical Analysis
The Kruskal-Wallis test was used to analyze age,
total ICU length of stay, and day of exitus, and gender,
admission category, and mortality rates were analyzed
using the chi-square test. The significance of
difference in the volume of fluid infused daily, CVP,
and MAP between the 3 groups was calculated using
the Kruskal-Wallis test. Serum glucose levels at the
start of therapy and at 96 h were analyzed using the
Kruskal-Wallis test, the existence of vasopressor (VP)
and diuretic therapy was analyzed using the chisquare test. Comparison of initial AST, ALT, ALP,
albumin, bilirubin, INR, BUN, creatinine, and mean
hourly urinary output was performed using the
Kruskal-Wallis test, and variations between the 2
therapy time points (the beginning and 96 h of
therapy) were determined using the Wilcoxon signedrank test.
Results
Patient characteristics
Based on digital archive data, 825 patients were
admitted to the ICU between January 2004 and
January 2006. From among these patients, data
recorded for 108 patients diagnosed with sepsis were
retrospectively evaluated. There were no significant
differences in age, gender, total ICU length of stay,
mortality rate, or day of exitus between the 3 groups.
Baseline demographic characteristics of the 108
patients included in the study are shown in Table 1.
The mortality rate in each group and total mortality
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Table 1. Demographic profile, ICU stay time, and mortality data of all patients. Age, Total ICU Stay, and Day
of Exitus Values are expressed as Median (Minimum – Maximum), mortality rate was defined by ratio
value.

APC group (n = 22)
IVIg group (n = 20)
ST group (n = 66)
†
P
Total (n = 108)
†

Age
(Year)

Gender
(M/F)

Total ICU Stay
(Day)

Mortality rate
(n/Ex) (%)

Day of Exitus
(Day)

57.5 (17-87)
64 (30-84)
63 (15-85)
0.579
63 (15-87)

14/8
15/5
37/29
0.303
66/42

23.5 (4-70)
17 (7-52)
17 (5-99)
0.515
18 (4-99)

22/15 (68%)
20/14 (70%)
66/56 (84%)
0.146
108/85 (78%)

21.5 (4-70)
17 (7-52)
16.5 (5-99)
0.833
23.5 (4-99)

The significance level of the parameters among the 3 groups.

rate (78%) is shown in Table 1. There were significant
differences between the groups according to
admission category of the patients, as shown in Table
2. There were no differences in terms of prognostic
factors, comorbidity, or bacterial gram species (+/-)

isolated between the 3 groups (Table 3). The mean
volume of fluid infused daily was similar in all 3
groups. The 6-h CVP was lower in the ST group than
in the other 2 groups (P = 0.004), and MAP at the start
of therapy, and 6 and 96 h later was significantly lower

Table 2. Admission category of the patients. Data were expressed as the number of
patient (n) in each group.
Admission Category
Emergency Room
Ward
Other Hospital
Postoperative
P
†

‡

IVIg group

APC group

ST group

7
12
1
0
†
0.011

11
9
0
2
0.048†

36
16
1
13
<0.0001‡

The level of significant distribution between the admission categories in IVIg group
and APC group cases.
The level of very significant distribution between the admission categories in the ST
group.

Table 3. The prognostic factors and comorbidity of patients and the identified bacterial gram
species in each group. Data were expressed as positive cases/n, and the rate (%).

Renal disease
Malignancy
Trauma
Hypertension
Diabetes Mellitus
Identified Bacterial Gram
Species (Positive/Negative)
‡
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‡

IVIg group

APC group

ST group

P

2/20 (10%)
0/20 (0%)
1/20 (5%)
2/20 (10%)
3/20 (15%)
10/10

3/22 (13.63%)
1/22 (4.54%)
4/22 (18.18%)
3/22 (13.63%)
2/22 (9.09%)
16/6

2/66 (3.03%)
4/66 (6.06%)
12/66 (18.18%)
8/66 (12.12%)
7/66 (10.60%)
41/25

0.168
0.528
0.344
0.936
0.841
0.317

The significance level of parameters among the 3 groups.
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in the ST group than in the other groups (P = 0.008
and P < 0.0001, respectively) (Table 4). There were no
significant differences in serum glucose levels or
diuretic therapy between the groups; however, 6- and
96-h vasopressor therapy were significantly different
in the ST group (P = 0.001 and P < 0.0001,
respectively) (Table 5).

APACHE II score was significantly lower in the APC
group than that in the IVIG group (P = 0.0018). The
96-h APACHE II score in the ST group was
significantly lower than that at 0 h (P = 0.019). In the
APC and IVIg groups the 96-h APACHE II score was
significantly lower than that at 0 h (P < 0.0001)
(Figure).

Renal and Hepatic Functions
All 3 groups were similar in terms of initial
hepatorenal function, according to AST, ALT,
albumin, INR, bilirubin, BUN, creatinine, and mean
hourly urinary output (Table 6). In the APC group the
AST level at 96 h was significantly lower than that at
baseline (0 h) (P = 0.035). In the ST group 96-h
bilirubin was lower than that at baseline (0 h) (P =
0.015). Hepatic functions in the 3 groups at 0 and 96
h are shown in Table 7. Renal functions (according to
BUN, creatinine, mean daily urinary output) did not
significantly differ between 0 and 96 h in the APC and
IVIg groups (Table 8).
APACHE II scores
APACHE II scores in the 3 groups were similar at
the start of therapy (P = 0.311), whereas the
differences in 96-h APACHE II scores between the 3
groups were significant. In the ST group the 96-h
APACHE II score was significantly higher than that
in the other 2 groups (P < 0.0001), and the 96-h

Discussion
The results of the present retrospective study show
that rhAPC and IgM-enriched immunoglobulin
therapy did not positively affect sepsis-related
hepatorenal dysfunction. Although the 96-h AST level
decreased significantly, with respect to 0 h, this
finding may not be considered clinically relevant, as
AST is not the only liver-specific enzyme. In the IVIg
group no improvement in hepatorenal functions was
observed.
In cases of severe sepsis and septic shock, the level
of functioning of any vital organ may be reduced,
regardless of the source of infection (14). In most fatal
sepsis cases patients experience an insidious,
progressive decline in vital organ function, i.e. MODS
(15). The liver plays a major role in modulating
systemic response in patients with severe sepsis,
because it contains most of the body’s macrophages
(Kuppfer cells) and is able to clear the endotoxins and

Table 4. CVP and MAP values at the beginning of the therapies and in the following 6 and 96 h, daily infused fluid amount also at the
beginning of the therapies and on the following 4th day. Data are expressed as medians (minimum-maximum). Daily infused
fluid amount is expressed as mL/day. Central Venous Pressure (CVP) and Mean Arterial Pressure (MAP) are expressed as
mmHg.

Daily infused fluid amount of
beginning of therapy day
Daily infused fluid amount on day 4
CVP of beginning of therapy
CVP at 6 h
CVP at 96 h
MAP at beginning of therapy
MAP at 6 h
MAP at 96 h
†
‡

IVIg group

APC group

ST group

P

5000 (4300-5300)

5000 (3500-5400)

5000 (3500-5400)

0.966

3700 (3400-4350)
2.5 (0-9)
8 (4-12)
8.5 (4-13)
70 (60-83)
74 (66-86)
78 (70-92)

3600 (2750-4300)
4 (0-9)
9 (6-13)
9 (6-12)
65.5 (59-85)
74 (62-86)
79.5 (70-89)

3700 (2750-4350)
3 (0-9)
6 (3-16)
9 (2-15)
64 (60-80)
63.5 (50-80)
62.5 (47-92)

0.804
0.483
0.004†
0.275
0.008†
<0.0001‡
<0.0001‡

Level of significant differences among IVIg group, APC group, and ST group
Level of very high significant differences among IVIg group, APC group, and ST group
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Table 5. Serum glucose levels, existence of diuretic therapy at the beginning of the therapies and on the following
4th day, presence of vasopressor therapy (VP) at the beginning of the therapies and in the following 6 h
and 4th day. Glucose data were expressed as median (minimum-maximum). Diuretic and vasopressor
data were expressed as positive case/n.

Glucose Levels beginning of therapy
Glucose Levels at 96 h
Diuretic use beginning of therapy
Diuretic use at 96 h
VP of beginning therapy
VP at 6 h
VP at 96 h
†
‡

IVIg group

APC group

ST group

P

131 (84-220)
120.5 (93-162)
2/20 (10%)
2/20 (10%)
15/20 (75%)
12/20 (60%)
2/20 (10%)

134.5 (72-230)
123.5 (83-142)
3/22 (13.63%)
4/22 (18.18%)
18/22 (81.81%)
13/22 (59.09%)
2/22 (9.09%)

132 (78-319)
137.5 (89-141)
6/66 (9.09%)
5/66 (7.57%)
61/66 (92.42%)
60/66 (90.9%)
9/66 (86.36%)

0.980
0.882
0.830
0.362
0.091
†
0.001
<0.0001‡

Significant differences among IVIg group, APC group and ST group
Very high significant differences among IVIg group, APC group and ST group

Table 6. Renal and hepatic functions data at the beginning of the therapies. Data are expressed as median
(minimum-maximum), AST and ALT (U/L), albumin, bilirubin, BUN, and creatinine (mg/dL), Hourly
urinary output (mL/h), and INR (ratio).

ALT

IVIg group

APC group

ST group

P†

29 (4-135)

35.5 (13-291)

25 (2-755)

0.175

AST

30.5 (8-109)

45 (16-163)

37 (7-289)

0.172

ALP

363 (359-571)

323 (135-364)

331 (208-503)

0.211

Albumin

3 (2.2-4.8)

3.1 (2.5-3.6)

3.2 (1.7-4.8)

0.843

Bilirubin

1 (0.16-5.7)

0.9 (0.01-11.9)

0.8 (0.05-3.7)

0.836

INR

1.13 (0.9-1.6)

1.14 (0.89-1.39)

1.2 (0.8-2.3)

0.262

BUN

30.35 (8-76)

27.5 (8-125)

27.5 (7-180)

0.859

Creatinine

0.84 (0.4-2.3)

1.05 (0.4-6.1)

0.9 (0.3-4.48)

0.496

Hourly Urinary Output

101 (48-230)

94.5 (39-203)

88 (5-222)

0.648

†

Significance level of differences among IVIg group, APC group, and ST group

bacteria that can stimulate systemic inflammatory
response. Hepatic injury has been investigated
primarily in critically ill patients, and few studies have
included only septic patients (4,15,16). Criteria used
to define hepatic injury include jaundice,
hyperbilirubinemia, elevated plasma concentrations
of transaminases, alkaline phosphatase, or lactate
dehydrogenase, and a decrease in the serum albumin
concentration. In cases of septic shock
aminotransferase (AST, ALT) levels are usually mildly
elevated and are disproportionately lower than
954

bilirubin levels (17). Unfortunately, conventional
hepatic function markers are either relatively nonspecific or have a long half-life, which make them
poor predictors of acute injury (18).
In our ICU patients ALT and AST are routinely
used to measure hepatic functions. ALT is primarily a
hepatic enzyme. The spillover of this enzyme into
blood is routinely used as a marker of hepatic-cell
damage. This helps to identify hepatic disease caused
by cell damage. The enzyme AST has a similar role,
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Table 7. ALT, AST, ALP, albumin, bilirubin, and INR value variations of groups during 2 time periods (zero as the beginning of the
therapies and +96 as 96 h of the therapies. Data were expressed as median (minimum-maximum), AST and ALT (U/L), albumin,
bilirubin (mg/dL), Hourly urinary output (ml/h), and INR (ratio).
Periods
IVIg group
(n = 20)

Zero
+96
†

P
APC group
(n = 22)

Zero
+96
P

ST group
(n = 66)

†

Zero
+96
P

†

ALT

AST

ALP

Albumin

Bilirubin

INR

43
(15-81)
34.5
(13-83)
0.480

46
(10-110)
36
(18-72)
0.374

363
(147-612)
245
(172-529)
0.655

2.95
(2.1-4.4)
2.8
(2.46-3.7)
0.824

1
(0.16-5.7)
0.7
(0.03-5.01)
0.180

1.09
(0.9-1.49)
1.2
(0.9-1.79)
0.126

68
(23-191)
51.5
(14-158)
0.082

66
(21-115)
48
(30-102)
0.035

335
(135-472)
213
(143-384)
0.180

2.85
(2.3-3.5)
2.9
(2.3-3.6)
0.320

0.94
(0.01-8.3)
0.9
(0.2-3)
0.754

1.27
(1-2.01)
1.11
(0.89-2.93)
0.500

25.5
(2-527)
34
(5-269)
0.424

41
(8-147)
49
(14-143)
0.481

366.5
(105-806)
413
(163-542)
0.180

2.85
(2-4.6)
2.9
(2-4.4)
0.417

1.36
(0.4-3.11)
1
(0.4-3)
0.015

1.2
(0.9-1.9)
1.21
(0.9-2.3)
0.450

†

Significance level between zero and +96 time periods. The statistically significant results appeared as decrease in AST levels in APC
group and in bilirubin levels in ST group.

Table 8. BUN, creatinine, and hourly average urinary output variations of groups during 2 time
periods (zero as the beginning of the therapies and +96 as 96 h of the therapies). Data
were expressed as median (minimum-maximum), BUN and creatinine data mg/L,
hourly average urinary output mL/h.
Periods

IVIg group
(n = 20)

Zero
+96
P†

APC group
(n = 22)

Zero
+96
P†

ST group
(n = 66)

Zero
+96
P†

†

BUN

Creatinine

Hourly average
urine output

30.35
(8-76)
45.5
(12-98.1)
0.061

0.84
(0.4-2.3)
0.86
(0.2-4.5)
0.349

101
(48-230)
124.5
(25-193)
0.877

27
(8-125)
30.35
(15-107)
0.198

1
(0.4-6.1)
0.85
(0.5-3.4)
0.234

96
(39-203)
90
(0-351)
0.717

27.5
(7-180)
35.5
(8-93)
0.096

0.9
(0.3-4.48)
0.9
(0.4-5.5)
0.641

88
(5-222)
109
(5-232)
0.850

Significance level of differences in groups between zero and +96 time periods
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31
29

27.95

27.2

28

26.83 ‡

27
25

22.6 †

23

20.13 †

21
19
17
15

Zero Hour
Group APC

96th Hour
Group IVIg

Group ST

Figure. APACHE II score variations 0 and 96 h after the
beginning of the therapies in 3 groups.
†

The significance of decrease in 96 h values compared to 0 h with
paired samples-t test in APC group and IVIg group; P < 0.0001

‡

The significance of decrease in 96 h values compared to 0 h with
paired samples-t test in ST group; P = 0.019

but this enzyme tends to be found in other tissues,
such as the heart, and therefore is not specific to the
liver (17). A recent study that included healthy
volunteers in whom sepsis was induced reported that
glutathione S-transferase A1-1 may be a useful
marker of early hepatic injury in septic shock patients
due to its relatively short half-life (1 h) and rapid
release into the blood after hepatic damage (18).
AST has a circulatory half-life of approximately
12-24 h; therefore, levels rise in response to hepatic
damage and clear quickly once damage ceases. ALT
has a longer half-life (37-57 h) than AST;
consequently, its elevation persists longer after hepatic
damage has ceased. In the present study we measured
AST and ALT levels at 96-h, a time interval that was
sufficiently long for evaluating changes in the long
half-life enzyme ALT in septic patients. However, 96h changes in this enzyme were not significant in any
of the groups, whereas AST decreased significantly in
the APC group.
Sepsis and septic shock remain the most important
triggers of acute renal failure (ARF) in ICU patients.
Despite the advent of sophisticated renal replacement
therapies that employ high-dose hemofiltration and
high-flux membranes, mortality and morbidity from
sepsis-induced acute kidney injury remain high (3).
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Patients with sepsis-related ARF have much higher
mortality than patients with acute renal failure that
do not have sepsis. A possible explanation for the high
incidence and poor outcome of septic ARF relates to
the lack of specific therapies (19), and a limited
understanding of septic-related acute renal injury and
its pathogenesis (20).
The question that remains is whether or not
adjuvant therapies, such as immunoglobulin
preparations and rhAPC, added to standard sepsis
therapy can improve sepsis-induced renal injury. In
the present retrospective study creatinine, BUN, and
mean hourly urinary output levels were taken into
consideration while evaluating the impact of adjuvant
therapy strategies on renal damage in septic ICU
patients. We did not observe any significant changes
in renal functions based on the data obtained from all
3 study groups.
There is a limited quantity of data on the
relationship between sepsis-related renal failure and
rhAPC therapy in the current literature. Gupta et al.
(21) recently reported that administration of rhAPC
protects against renal dysfunction, but the underlying
mechanism is unknown. An experimental study
performed by the same researchers reported that
serine protease protein C levels during systemic
inflammatory response may be pathophysiologically
related to renal dysfunction, and that the ability to
improve renal function and pathology suggests the
potential for the clinical use of rhAPC in the
treatment of sepsis-induced ARF (22). Moreover,
Mikaszewska-Sokolewicz et al. (23) reported there
was improvement in renal excretory function after
rhAPC infusion in 2 septic ICU patients. Such studies
highlight the role of protein C and activated protein C.
In the present retrospective study significant
improvement in renal function in the patients
administered activated protein C was not observed;
however, we think because only 108 patients were
evaluated the results obtained are limited, and that
additional research including larger groups of septic
patients is needed.
IgM-enriched immunoglobulin is a promising
adjuvant therapy, both clinically and economically,
for the treatment of adults with severe sepsis and
septic shock (14). The efficacy of polyclonal
immunoglobulins in therapy for sepsis and septic
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shock was supported for the first time by various trials
that were collected in a recent Cochrane Library
meta-analysis (6). Clinical studies indicate there are
potential differences in the efficacy of
immunoglobulin preparations in patients with sepsis
(24). Sepsis remains one of the important causes of
vital organ dysfunction. In addition to standard

treatment regimens, new adjuvant agents are in
clinical use; however, the cost/benefit ratio raises
questions about the feasibility of their use in sepsis
patients. This fact also makes planning prospective
trials difficult. We hope that future clinical trials that
evaluate the benefits of these agents on multi-organ
dysfunction will provide promising results.
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